Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...

Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

5. Hims and Hers Hims and Hers have been go-to brands for a while—think hair loss, skincare, and all that good stuff. They’re now offering weight loss meds like semaglutide, which is great if you’re ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly’s obesity and diabetes drugs are no longer ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

If you’re dealing with male pattern baldness, there’s a good chance you’ve heard of or use finasteride. You also may have ...

If you’re reading this because you’re losing your hair, you’re not alone — hair loss is a common issue affecting more than ...

Also Read: Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel. Many people opting for compounded GLP-1s cite lower costs ...